Epitope-Specific Anti-SEMA4D Antibodies for Tumor Vascularity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for SEMA4D neutralizing molecules, such as anti-SEMA4D antibodies, to treat cancers and neuroinflammatory diseases, as SEMA4D plays a role in demyelination, axonal degeneration, and promotes angiogenesis and tumor growth.
Innovation Solution
Development of epitope-specific binding agents, including antibodies and antigen-binding fragments, that target SEMA4D to block its interaction with receptors like Plexin-B1, thereby inhibiting its signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-SEMA4D antibodies are developed to neutralize SEMA4D, then tumor vascularity and inflammatory responses are reduced, but the complexity of producing and characterizing epitope-specific binding agents increases
Solution Approach 1:
The patent identifies and targets specific epitopes (linear or conformational) on the SEMA4D protein surface. By segmenting the antigen into distinct epitopic regions, the invention enables selective neutralization of harmful SEMA4D functions while maintaining production feasibility through focused antibody development against specific epitope sites.
Solution Approach 2:
The patent uses epitope-specific binding agents (antibodies or antibody fragments) as intermediary molecules that mediate between the SEMA4D protein and the therapeutic effect. These binding agents block SEMA4D-receptor interactions and neutralize harmful signals, thereby reducing tumor vascularity and inflammatory responses without directly altering the SEMA4D protein itself.
2Object-generated harmful factors
If binding agents are used to block SEMA4D-receptor interactions, then signaling pathways are inhibited, but the difficulty of detecting and measuring binding specificity increases
Solution Approach 1:
The patent employs epitope mapping techniques that utilize detectable signals (analogous to color changes in detection) to identify and characterize specific binding interactions between binding agents and SEMA4D epitopes. This enables verification of binding specificity and facilitates the development of agents with high affinity for target epitopes.
Solution Approach 2:
The patent incorporates epitope mapping and characterization procedures that provide feedback on binding agent performance. By systematically evaluating binding specificity, affinity, and functional blocking activity, the invention optimizes binding agents to achieve effective inhibition of SEMA4D signaling pathways while maintaining measurable and verifiable binding characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding agents effectively neutralize SEMA4D, potentially reducing tumor vascularity, inhibiting endothelial cell migration, and mitigating inflammatory responses in neuroinflammatory diseases, providing a therapeutic approach for SEMA4D-related conditions.
Implementation Method 1
Development of epitope-specific binding agents, including antibodies and antigen-binding fragments, that target SEMA4D to block its interaction with receptors like Plexin-B1
Data Source
AI summary
The invention relates to epitopes of SEMA4D and to binding agents, such as antibodies, that specifically bind to SEMA4D.